Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ouch, Canada! Prexige Withdrawn From Yet Another Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Ottawa withdraws marketing authorization for Novartis’ troubled anti-inflammatory drug due to the potential for serious liver damage.

You may also be interested in...



Sales of Novartis’ Prexige Suspended in U.K., Germany, Austria After EU Announces Safety Review

EU’s Article 107 procedure was prompted by U.K. sanctions imposed in August after two Australian patients died from liver damage.

Sales of Novartis’ Prexige Suspended in U.K., Germany, Austria After EU Announces Safety Review

EU’s Article 107 procedure was prompted by U.K. sanctions imposed in August after two Australian patients died from liver damage.

No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA

Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel